Skip to main content

Randomized cross-over trial comparing inpatient and outpatient administration of high-dose cisplatin

Buy Article:

$51.00 plus tax (Refund Policy)

Abstract:

Abstract Background/Aims:

Treatment with high-dose cisplatin (HDC) previously required inpatient (IP) admission with overnight hospitalization, but recently practice has shifted to outpatient (OP) therapy. We aimed to determine whether it is preferable to give HDC as an IP or OP using a two-period cross-over trial. Methods:

Eligible patients were starting chemotherapy with ≥2 cycles of HDC (≥100 mg/dose) and were suitable for OP treatment. All patients received an IP cycle and OP cycle: the order was randomly allocated. Pre-hydration, anti-emetics and chemotherapy were identical for IP and OP. Post-hydration varied by group (3 L normal saline (NS) for IP, 2 L NS for OP). The primary outcome was patient preference for IP versus OP treatment. Secondary outcomes included aspects of health-related quality of life, adverse events (dose delays and reductions, elevated creatinine and unplanned readmissions) and resource use. Results:

Fifty-nine patients were randomized, 53 completed two cycles of HDC. Most patients preferred OP treatment (36 vs 13, P= 0.002). There were no significant differences in patients' ratings of nausea, vomiting, fatigue, anxiety, depression or overall quality of life. Adverse events were few and unrelated to IP versus OP treatment. Nursing time was longer for IP than OP (163 vs 104 min, P < 0.001). Conclusion:

OP treatment was preferred by most patients, appeared safe and used less resources.

Keywords: cisplatin; health services; inpatient; outpatient; patient preference

Document Type: Research Article

DOI: http://dx.doi.org/10.1111/j.1445-5994.2010.02201.x

Affiliations: 1: Sydney Cancer Centre, Royal Prince Alfred Hospital, 2: National Health and Medical Research Council Clinical Trials Centre, University of Sydney and

Publication date: February 1, 2011

bsc/imj/2011/00000041/00000002/art00007
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more